Voyager Therapeutics (VYGR) Accumulated Expenses (2014 - 2026)

Voyager Therapeutics has disclosed Accumulated Expenses across 13 years of filings, most recently posting $3.3 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $3.3 million, down 63.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 million (down 63.47% YoY), and the FY2025 annual result was $9.1 million, up 34.64% from the prior year.
• Accumulated Expenses came in at $3.3 million for Q1 2026 at Voyager Therapeutics, down from $9.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $16.8 million in Q4 2023 to a low of $2.5 million in Q1 2023.
• The 5-year median for Accumulated Expenses is $7.7 million (2022), against an average of $8.1 million.
• Across the five-year window, Accumulated Expenses sank 74.45% in 2022 and jumped 269.01% in 2023, its largest moves.
• Voyager Therapeutics' Accumulated Expenses stood at $4.6 million in 2022, then surged by 269.01% to $16.8 million in 2023, then plunged by 59.86% to $6.8 million in 2024, then jumped by 34.64% to $9.1 million in 2025, then sank by 63.62% to $3.3 million in 2026.
• The last three Accumulated Expenses figures came in at $3.3 million (Q1 2026), $9.1 million (Q4 2025), and $15.0 million (Q3 2025), per Business Quant data.